Biotech strategy and nanomedicine: the pharmaphorum podcastFor episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Share XBiotech strategy and nanomedicine: the pharmaphorum podcasthttps://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/
Commercialising orphan drugs: the pharmaphorum podcastIn episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Share XCommercialising orphan drugs: the pharmaphorum podcasthttps://pharmaphorum.com/r-d/views-analysis-r-d/orphan-drugs-pharmaphorum-podcast/
The future biosimilar landscape: the pharmaphorum podcastFor episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet Share XThe future biosimilar landscape: the pharmaphorum podcasthttps://pharmaphorum.com/sales-marketing/the-future-biosimilar-landscape/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
